Basil Sharrack

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

A genetic study of Wilson’s disease in the United Kingdom

Alison J. Coffey, Miranda Durkie, Stephen Hague et al. · Brain · 2013 · 362 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

The effect of anti-α4 integrin antibody on brain lesion activity in MS

Niall Tubridy, P. O. Behan, Rudy Capildeo et al. · Neurology · 1999 · 308 citations

Pharmacy, Neurology, Pharmacotherapy +16

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis

Richard K. Burt, Roumen Balabanov, Joachim Burman et al. · JAMA · 2019 · 300 citations · Full text

Medicine, Neurology, Cell Therapy +14